Expertise in
5
conditions

Dr. Mark H. Kogan

Gastroenterology
1041 N China Lake Blvd, Ste B, 
Ridgecrest, CA 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
5
conditions
1041 N China Lake Blvd, Ste B, 
Ridgecrest, CA 

Overview

Mark Kogan is a Gastroenterologist practicing medicine in Ridgecrest, California.

Dr. Kogan is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Ulcerative Colitis, Primary Biliary Cholangitis, Reynolds Syndrome, Endoscopy, and Gastrectomy.

Dr. Kogan is board certified in Internal Medicine (Sub: Gastroenterology) and Internal Medicine. He is actively involved in clinical research, participating in 9 clinical trials. Dr. Kogan is currently accepting new patients.

Specialties

Gastroenterology

Licenses

Internal Medicine in CA

Board Certifications

Internal Medicine (Sub: Gastroenterology)
Internal Medicine

Fellowships

University of Colorado Health Science Center

Hospital Affiliations

Contra Costa Regional Medical Center
Alta Bates Summit Medical Center
Ridgecrest Regional Hospital
Alta Bates Summit Medical Center - Alta Bates Camp

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Contra Costa Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

HMSA
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Sutter Health
  • HMO
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

Ridgecrest Regional Hospital
1041 N China Lake Blvd, Ste B, Ridgecrest, CA 93555

Additional Areas of Focus

Dr. Kogan has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Enrollment Status: Completed
Publish Date: May 13, 2026
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2026
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
Enrollment Status: Completed
Publish Date: June 21, 2024
Intervention Type: Drug
Study Drug: Ontamalimab
Study Phase: Phase 3
A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo-Controlled Study of LY3074828 in Subjects With Active Crohn's Disease (SERENITY)
A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo-Controlled Study of LY3074828 in Subjects With Active Crohn's Disease (SERENITY)
Enrollment Status: Completed
Publish Date: August 30, 2022
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 2
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 307)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 307)
Enrollment Status: Terminated
Publish Date: March 31, 2022
Intervention Type: Drug, Other
Study Drug: Ontamalimab
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
Enrollment Status: Completed
Publish Date: January 14, 2022
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 306)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 306)
Enrollment Status: Terminated
Publish Date: May 11, 2021
Intervention Type: Other, Biological
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 302)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 302)
Enrollment Status: Terminated
Publish Date: April 26, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 8 Less Clinical Trials
Similar Doctors
Expertise in
71
conditions
Expertise in
71
conditions
Referral may be required
Before you request

Adventist Health Medical Center Tehachapi

105 W E St, 
Tehachapi, CA 
 (56.2 miles away)
661-823-7070
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Kumaravel Perumalsamy is a Gastroenterologist practicing medicine in Tehachapi, California. Dr. Perumalsamy is highly rated in 71 conditions, according to our data. His clinical expertise encompasses Swallowing Difficulty, Painful Swallowing, Gastroesophageal Reflux Disease (GERD), Gastrectomy, and Gastrostomy. Dr. Perumalsamy is currently accepting new patients.

Expertise in
58
conditions
Dr. Duminda B. Suraweera
Gastroenterology
Expertise in
58
conditions
Dr. Duminda B. Suraweera
Gastroenterology
Referral may be required

Adventist Health Community Care-Tehachapi

105 W E St, 
Tehachapi, CA 
 (56.2 miles away)
661-771-8222
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Duminda Suraweera is a Gastroenterologist practicing medicine in Tehachapi, California. Dr. Suraweera is highly rated in 58 conditions, according to our data. His clinical expertise encompasses Gastroesophageal Reflux Disease (GERD), Gastritis, Swallowing Difficulty, Gastrectomy, and Gastrostomy.

Expertise in
7
conditions
Dr. Waleed W. Shindy
Gastroenterology
Expertise in
7
conditions
Dr. Waleed W. Shindy
Gastroenterology
Referral may be required
Before you request

Ridgecrest Regional Hospital

1081 N China Lake Blvd, 
Ridgecrest, CA 
 (0.1 miles away)
760-446-3551
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Waleed Shindy is a Gastroenterologist practicing medicine in Ridgecrest, California. Dr. Shindy is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Swallowing Difficulty, Painful Swallowing, Gas Bloat Syndrome, Gastrectomy, and Endoscopy. Dr. Shindy is board certified in American Board Of Internal Medicine. Dr. Shindy is currently accepting new patients.

Frequently Asked Questions about Dr. Mark H. Kogan

How do I make an appointment with Dr. Mark H. Kogan?

You can book an appointment with Dr. Mark H. Kogan by calling their office at 760-446-8692. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Mark H. Kogan a top-rated expert for Ulcerative Colitis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Mark H. Kogan is classified as an Advanced expert for Ulcerative Colitis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Mark H. Kogan specialize in?

While Dr. Mark H. Kogan is a Gastroenterology, they have specific expertise in Ulcerative Colitis, Primary Biliary Cholangitis, and Reynolds Syndrome. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Gastroenterology.

Does Dr. Mark H. Kogan accept my insurance?

Dr. Mark H. Kogan accepts most major insurance plans, including Aetna and Alignment Health Plan. We recommend calling the office directly at 760-446-8692 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kogan's expertise for a condition
ConditionClose
      View All 47 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile